Oncorus (NASDAQ:ONCR) Stock Price Down 6%

Oncorus, Inc. (NASDAQ:ONCRGet Rating) shares were down 6% during mid-day trading on Friday . The stock traded as low as $0.37 and last traded at $0.40. Approximately 363,009 shares changed hands during trading, a decline of 55% from the average daily volume of 806,408 shares. The stock had previously closed at $0.42.

Analyst Ratings Changes

Several equities analysts recently issued reports on ONCR shares. HC Wainwright lowered Oncorus from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 6th. Chardan Capital lowered Oncorus from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 30th. Finally, Piper Sandler lowered Oncorus from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $6.00 to $2.00 in a research note on Wednesday, November 30th.

Oncorus Trading Down 6.0 %

The company has a fifty day simple moving average of $0.41 and a two-hundred day simple moving average of $0.86. The company has a current ratio of 4.97, a quick ratio of 4.97 and a debt-to-equity ratio of 0.24. The company has a market cap of $10.26 million, a PE ratio of -0.13 and a beta of 2.42.

Oncorus (NASDAQ:ONCRGet Rating) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.01. Analysts anticipate that Oncorus, Inc. will post -2.85 EPS for the current year.

Insider Activity

In other news, major shareholder James E. Flynn sold 141,753 shares of the stock in a transaction dated Thursday, December 29th. The stock was sold at an average price of $0.26, for a total value of $36,855.78. Following the transaction, the insider now owns 299,917 shares in the company, valued at approximately $77,978.42. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, major shareholder James E. Flynn sold 141,753 shares of the stock in a transaction dated Thursday, December 29th. The stock was sold at an average price of $0.26, for a total value of $36,855.78. Following the transaction, the insider now owns 299,917 shares in the company, valued at approximately $77,978.42. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder James E. Flynn sold 99,718 shares of the stock in a transaction dated Monday, December 19th. The shares were sold at an average price of $0.29, for a total value of $28,918.22. Following the completion of the transaction, the insider now owns 332,725 shares in the company, valued at approximately $96,490.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 325,547 shares of company stock worth $89,553. 15.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Sawtooth Solutions LLC boosted its position in shares of Oncorus by 22.9% in the 2nd quarter. Sawtooth Solutions LLC now owns 77,336 shares of the company’s stock valued at $97,000 after purchasing an additional 14,433 shares during the period. Private Advisor Group LLC boosted its position in shares of Oncorus by 28.9% in the 2nd quarter. Private Advisor Group LLC now owns 81,304 shares of the company’s stock valued at $103,000 after purchasing an additional 18,220 shares during the period. Hsbc Holdings PLC acquired a new stake in shares of Oncorus in the 1st quarter valued at about $39,000. Goldman Sachs Group Inc. boosted its position in shares of Oncorus by 35.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 117,925 shares of the company’s stock valued at $148,000 after purchasing an additional 30,668 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Oncorus by 23.9% in the 2nd quarter. Renaissance Technologies LLC now owns 217,450 shares of the company’s stock valued at $274,000 after purchasing an additional 41,918 shares during the period. Hedge funds and other institutional investors own 63.69% of the company’s stock.

About Oncorus

(Get Rating)

Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.

Featured Stories

Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.